SAB Biotherapeutics Inc
NASDAQ:SABS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
SAB Biotherapeutics Inc
PP&E Gross
SAB Biotherapeutics Inc
PP&E Gross Peer Comparison
SAB Biotherapeutics Inc
Glance View
SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company. The company is headquartered in Sioux Falls, South Dakota and currently employs 139 full-time employees. The company went IPO on 2021-01-12. The firm offers therapeutic engine called the DiversitAb platform, to produce a new class of specifically targeted, polyclonal antibodies without the need for human donors. Its DiversitAb platform enables a production of polyclonal antibody therapies with the to address the emergence, mutation, and diversity of modern health challenges including COVID-19, seasonal influenza, Type 1 diabetes, and cancers. Its product candidates include SAB-176, SAB-185, SAB-142 and SAB-181. The firm is developing new class of immunotherapies, leveraging the native human immune response, across therapeutic categories including infectious disease immune system disorders and immuno-oncology.
See Also
What is SAB Biotherapeutics Inc's PP&E Gross?
PP&E Gross
19.4m
USD
Based on the financial report for Dec 31, 2025, SAB Biotherapeutics Inc's PP&E Gross amounts to 19.4m USD.
What is SAB Biotherapeutics Inc's PP&E Gross growth rate?
PP&E Gross CAGR 5Y
-3%
Over the last year, the PP&E Gross growth was -3%. The average annual PP&E Gross growth rates for SAB Biotherapeutics Inc have been -12% over the past three years , -3% over the past five years .
